{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:07:28Z","timestamp":1785161248447,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,6]]},"DOI":"10.7759\/cureus.34696","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:37:36Z","timestamp":1675730256000},"source":"Crossref","is-referenced-by-count":3,"title":["A Rare Case of Pembrolizumab-Associated Graves\u2019 Disease"],"prefix":"10.7759","author":[{"given":"Sura","family":"Alqaisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck L","year":"2017","unstructured":"Dyck L, Mills KH. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017, 47:765-79. 10.1002\/eji.201646875","journal-title":"Eur J Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin P","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018, 50:1-11. 10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee H","year":"2017","unstructured":"Lee H, Hodi FS, Giobbie-Hurder A, et al.. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol Res. 2017, 5:1133-40. 10.1158\/2326-6066.CIR-17-0208","journal-title":"Cancer Immunol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0123","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"2022","author":"Cunha C","year":"2022","unstructured":"Cunha C, Silva E, Vieira AC, Saraiva C, Duarte S. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer. Endocrinol Diabetes Metab Case Rep. 2022, 2022:21-0123. 10.1530\/EDM-21-0123","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref5","article-title":"Pembrolizumab","author":"Flynn JP","year":"2022","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally RK","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020, 12:738. 10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak SJ","year":"2021","unstructured":"Casak SJ, Marcus L, Fashoyin-Aje L, et al.. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021, 27:4680-4. 10.1158\/1078-0432.CCR-21-0557","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267433","article-title":"Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy","volume":"14","author":"Ai L","year":"2020","unstructured":"Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X. Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020, 14:3625-49. 10.2147\/DDDT.S267433","journal-title":"Drug Des Devel Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette J","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016, 101:4431-9. 10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081944","article-title":"Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review)","volume":"13","author":"Peiffert M","year":"2021","unstructured":"Peiffert M, Cugnet-Anceau C, Dalle S, et al.. Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review). Cancers (Basel). 2021, 13:1944. 10.3390\/cancers13081944","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SAT-584","article-title":"SAT-584 pembrolizumab-related Graves\u2019 disease: a rare adverse effect of an anti-PD-1 antibody cancer immunotherapy","volume":"3","author":"Narayen G","year":"2019","unstructured":"Narayen G, Lieb D. SAT-584 pembrolizumab-related Graves\u2019 disease: a rare adverse effect of an anti-PD-1 antibody cancer immunotherapy. J Endocr Soc. 2019, 3:SAT-584. 10.1210\/js.2019-SAT-584","journal-title":"J Endocr Soc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1979","article-title":"Case of hyperthyroidism in a patient on anti-PD-1 (programmed cell death receptor-1 blocking antibody) therapy caused by destructive thyroiditis followed by Graves\u2019 disease","volume":"5","author":"Reddy C","year":"2021","unstructured":"Reddy C, Zena M. Case of hyperthyroidism in a patient on anti-PD-1 (programmed cell death receptor-1 blocking antibody) therapy caused by destructive thyroiditis followed by Graves\u2019 disease. J Endocr Soc. 2021, 5:A968-9. 10.1210\/jendso\/bvab048.1979","journal-title":"J Endocr Soc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000501824","article-title":"Graves\u2019 disease induced by immune checkpoint inhibitors: a case report and review of the literature","volume":"8","author":"Brancatella A","year":"2019","unstructured":"Brancatella A, Viola N, Brogioni S, et al.. Graves\u2019 disease induced by immune checkpoint inhibitors: a case report and review of the literature. Eur Thyroid J. 2019, 8:192-5. 10.1159\/000501824","journal-title":"Eur Thyroid J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2314032","article-title":"A case report of Graves\u2019 disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient","volume":"2019","author":"Yajima K","year":"2019","unstructured":"Yajima K, Akise Y. A case report of Graves\u2019 disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep Endocrinol. 2019, 2019:2314032. 10.1155\/2019\/2314032","journal-title":"Case Rep Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio JC","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, et al.. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017, 28:583-9. 10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis DA","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al.. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017, 102:2770-80. 10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2018.01.006","article-title":"A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy","volume":"22","author":"Park ES","year":"2018","unstructured":"Park ES, Rabinowits G, Hamnvik OR, Dagi LR. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS. 2018, 22:310-2. 10.1016\/j.jaapos.2018.01.006","journal-title":"J AAPOS"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/135347-a-rare-case-of-pembrolizumab-associated-graves-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:25Z","timestamp":1707508765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/135347-a-rare-case-of-pembrolizumab-associated-graves-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.34696","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}